- Market
Psychedelic Therapy (Psilocybin-Assisted Services)
- Region
Europe
- Growth
- CAGR 2019 2024
7.8
- CAGR 2024 2030 Base
9.1
- CAGR 2024 2030 Downside
4
- Drivers
Pilot programs in the UK, Netherlands, and Switzerland; increasing research funding; advocacy for mental health innovation.
- Risks
Strict regulatory barriers; slow reimbursement adoption; fragmented policy landscape.
- Distribution
- Market Size
324000000
- Share
18
- Footnotes
- line1
1) Market size includes legal and regulated psilocybin-assisted therapy services and clinical trial-related revenues; excludes illicit and unregulated use.
- line2
2) Growth projections assume continued regulatory progress in North America and Oceania; downside scenario reflects potential policy reversals or slower adoption.
- source
Askpot AI Analysis Report 2025
Psychedelic Therapy (Psilocybin-Assisted Services) — Europe market analysis
The global psychedelic therapy market is in an early growth phase, with North America leading due to progressive regulatory changes and clinical adoption. Psilocybin-assisted therapy is gaining traction for treatment-resistant depression, PTSD, and end-of-life anxiety, but remains largely restricted to clinical trials or pilot programs outside select US states. Market expansion is closely tied to evolving legal frameworks, clinical evidence, and public acceptance.